All In Biotech

Drug Trial Radar · NCT01147809

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin

Last checked: Nov 20, 2026Latest source record: Apr 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Jun 2010

Primary completion

Jan 2015

Study completion Mar 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.

Conditions

  • Thrombocytopaenia

Interventions

  • Eltrombopag olamineDrug

    thrombopoietin receptor agonist

  • PlaceboOther

    Placebo tablets with no active pharmaceutical ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase ITime frame: From Cycle 1, Day 1 (C1D1) until at least 30 days post-investigational product discontinuation (longer for AEs considered related to study participation)
  2. Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase ITime frame: After Baseline (C1D1), on-treatment and 30 day follow-up
  3. Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase ITime frame: After Baseline (C1D1), on-treatment and 30 day follow-up
  4. Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase ITime frame: After Baseline (C1D1), on-treatment and 30 day follow-up
  5. Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase ITime frame: Screening, C1D1, C2D1, C2D8, C2D15, C3D1, C4D1, C4D22, C5D1, C5D8, C6D1, C6D15
  6. Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase ITime frame: C2D4, C2D8, C5D8, C6D15
  7. Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase IITime frame: Day 1 (averaged across cycles 1 to 6)

Locations

86 sites in 13 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Sedona, Arizona

  • GSK Investigational Site

    Hot Springs, Arkansas

  • GSK Investigational Site

    Rancho Cucamonga, California

  • GSK Investigational Site

    Norwich, Connecticut

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    New Port Richey, Florida

  • GSK Investigational Site

    Rome, Georgia

  • GSK Investigational Site

    Savannah, Georgia

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Bethesda, Maryland

  • GSK Investigational Site

    Rockville, Maryland

  • GSK Investigational Site

    Columbia, Missouri

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Cherry Hill, New Jersey

  • GSK Investigational Site

    Albany, New York

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Bend, Oregon

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Wynnewood, Pennsylvania

  • GSK Investigational Site

    Providence, Rhode Island

  • GSK Investigational Site

    Providence, Rhode Island

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Arlington, Texas

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Bedford, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Tyler, Texas

  • GSK Investigational Site

    Norfolk, Virginia

  • GSK Investigational Site

    Edmonds, Washington

  • GSK Investigational Site

    Tacoma, Washington

  • GSK Investigational Site

    Vancouver, Washington

  • GSK Investigational Site

    Yakima, Washington

  • GSK Investigational Site

    Charleroi, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Libramont, Belgium

  • GSK Investigational Site

    Namur, Belgium

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Olomouc, Czechia

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.